Re:NewCell AB (publ)
STOCKHOLM, SE / ACCESSWIRE / October 19, 2021 / Re:NewCell AB (publ) (FRA:6QP) (STO:RENEW) Today, Renewcell and Kelheim Fibres Gmbh have signed a Letter of Intent for a long term commercial collaboration to add the crucial missing link for a circular economy for textiles in Europe. Together, the two technology leaders will collaborate on developing commercial scale production of superior quality viscose fibers from up to 10 000 tonnes of Renewcell's 100% textile recycled material Circulose® annually. The collaboration paves the way toward a fully European closed loop in which textile waste is collected, recycled and regenerated into new Circulose® fibers for people that want to reduce their fashion footprint significantly.
"European fashion consumption has great impact on climate and the environment globally. It also contributes to tremendous amounts of waste going into landfill and incinerators either in Europe or abroad after export. We will now work with Kelheim to prevent waste and reduce the need for virgin resources, while also enabling a fully regional supply of low impact circular fibers for textiles" comments Patrik Lundström, CEO of Renewcell. "We are thrilled for the opportunity to work closely with a partner like Kelheim, who is at the leading edge of innovation and sustainability in this industry" he adds.
Craig Barker, CEO at Kelheim Fibres adds: "We see an excellent fit between our two companies, not only on the technical side - with Renewcell we have found a highly professional partner who shares our vision for future-forward technologies that enable full circularity in the textile chain. Finding the answers to the challenges of our times is what drives us every day.
Our recycled cellulose fibre solution - made of Renewcell's Circulose® and manufactured using environmentally sound processes at our Kelheim plant - is an answer to the fashion industries need for sustainable, resource- and waste-reducing solutions, and a more regional and reliable supply chain."
About Renewcell
Founded by innovators from Stockholm's KTH Royal Institute of Technology in 2012, Re:NewCell AB (publ) (‘Renewcell') is a multi-award-winning sustaintech company based in Sweden. The company's vision is to inspire an Industrial Evolution to a sustainable world by producing high quality materials from recycled textiles.
Through its patented process, Renewcell is able to upcycle cellulosic textile waste, such as cotton clothes, transforming it into a pristine new material called Circulose®. Fast Company name Renewcell as one of the World's Most Innovative Companies 2021. Circulose® was also included on TIME Magazine's list of the 100 Best Inventions 2020.
Renewcell is a publicly listed company with shares traded on Nasdaq First North Premier Growth
Market with the ticker name RENEW and ISIN code SE0014960431. FNCA Sweden AB is Renewcell's Certified Adviser, +46(0)8-528 00 399, info@fnca.se .
CONTACT:
Presskontakt Renewcell
Harald Cavalli-Björkman
harald.cavalli-bjorkman@renewcell.com
+46 70 590 32 04
About Kelheim Fibres
Kelheim Fibres GmbH is the world's leading manufacturer of viscose speciality fibres.Innovative products, flexible technologies and an exceptional focus on sustainability form the foundation of the company's success.
Our plant-based speciality fibres are used in most diverse applications from fashion, hygiene and medical products to nonwovens and speciality papers. They offer an environmentally sound alternative to petroleum-based materials in a broad range of different end products - while maintaining or even enhancing the functional performance of the product. The production takes place exclusively in Germany and complies with the strict German environmental legislation. Our closed-loop philosophy and an energy-efficient way to operate our plants help to save valuable resources. Kelheim Fibres is the first viscose manufacturer worldwide with an EMAS-validated environmental management system. www.kelheim-fibres.com
PR Contact Kelheim Fibres
Stefanie Heigl
Tel: +49 9971 99 63 659
E-Mail: stefanie.heigl@kelheim-fibres.com
Image Attachments
Patrik Lundström, CEO Renewcell
Attachments
Renewcell and Kelheim Fibres form collaboration to establish a European closed loop for fashion
SOURCE: Re:NewCell AB (publ)
View source version on accesswire.com:
https://www.accesswire.com/668697/Renewcell-and-Kelheim-Fibres-Form-Collaboration-to-Establish-a-European-Closed-Loop-for-Fashion
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Karbon-X Advances Community-Led Forest Protection in Colombia's Meta Region19.11.2025 15:00:00 CET | Press release
New phase of the Sur del Meta Project expands carbon and biodiversity monitoring while strengthening local governance and livelihoods. CALGARY, AB / ACCESS Newswire / November 19, 2025 / In the heart of Colombia's Meta department, where forests and farmlands converge, Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company") is deepening its commitment to people-powered climate solutions through the REDD+ Sur del Meta Project - a long-term conservation initiative that protects 40,637 hectares of natural forest while supporting sustainable livelihoods for nearly 1,000 local families. Developed through ALLCOT - A Karbon-X Company, the project development and advisory arm of Karbon-X, the initiative operates across the municipalities of Vistahermosa, Puerto Rico, Puerto Concordia, and Puerto Lleras, a region historically affected by deforestation and armed conflict. The project partners with local farmers, many of whom are victims of Colombia's armed conflict, helping them transition from
eComplete Partners with Sourceful to build AI-Native Creative Operations Across Portfolio18.11.2025 15:00:00 CET | Press release
MANCHESTER, UK / ACCESS Newswire / November 18, 2025 / eComplete, the private equity firm behind Current Body's £300 million London Stock Exchange listing, has announced a strategic partnership with Sourceful, the Manchester-based technology company whose Riverflow 1 model ranks as the world's leading AI image editing model. The partnership brings Sourceful's AI-native creative platform to eComplete's portfolio of direct-to-consumer brands, enabling them to generate brand-accurate, production-ready creative assets at scale across e-commerce, social, marketplace and retail. This makes eComplete the first major private equity investor to adopt AI-native creative infrastructure as a core operational advantage. Why this matters Every consumer brand today faces the same constraint: producing thousands of creative assets, product images, ads, videos, packaging, that feel authentically on-brand across every channel and market. This challenge has intensified dramatically over the past three ye
IXOPAY Appoints George Hansen as Chief Revenue Officer to Accelerate Global Growth in Tokenization, Orchestration, and Compliance18.11.2025 06:00:00 CET | Press release
Seasoned payments executive joins IXOPAY to lead global revenue strategy amid rapid growth and the rise of agentic commerce. LEHI, UTAH / ACCESS Newswire / November 18, 2025 / IXOPAY, a global leader in enterprise-grade payment orchestration, today announced the appointment of George Hansen as Chief Revenue Officer (CRO). A veteran of the payments and fintech industries, Hansen brings more than two decades of leadership experience driving growth, transformation, and customer-centric innovation at a global scale. In his new role, Hansen will drive IXOPAY's global revenue strategy, leading sales and partnerships and aligning with marketing and customer success to support enterprise merchants and partners worldwide. His appointment reinforces IXOPAY's commitment to giving merchants full control of their payment strategy through a vendor-neutral architecture designed for scale, flexibility, and intelligence. Hansen has held senior leadership positions at companies including American Expres
General Holdings Limited and NewOak Capital Form Strategic Joint Venture to Launch CMXG, an $800M Commodities Investment Platform18.11.2025 06:00:00 CET | Press release
DUBAI, AE / ACCESS Newswire / November 18, 2025 / General Holdings Limited (GH), a Dubai International Financial Centre-based multi-strategy private investment holding company, and NewOak Capital LLC, a New York collateralized private debt asset management and structured financing and capital markets firm, today announced the formation of Common Commodities CMXG (CMXG), a vertically integrated tech-enabled commodities investment platform designed to deliver risk-controlled, scalable institutional commodity-linked real yield and growth equity to qualified global investors. The partnership combines General Holdings' strategic capital and governance expertise with NewOak Capital's structured asset-based supply-chain financing capabilities and distribution platform. This sets the foundation for "a globally scalable, integrated and transparent institutional trade finance platform facilitating sustainable and inclusive cross-regional growth." Strategic Capital Deployment and Fund Launch CMXG
OBI-902 Has Been Granted by US FDA for Orphan Drug Designation for the Treatment of Cholangiocarcinoma17.11.2025 13:00:00 CET | Press release
OBI-902 is the first ADC utilizing OBI's proprietary GlycOBI® glycan-based ADC enabling technology for evaluation of safety and efficacy in patients with Cancer. TAIPEI, TW / ACCESS Newswire / November 17, 2025 / OBI Pharma, a clinical-stage oncology company (4174.TWO) received notification from the US FDA stating that the request for Orphan Drug Designation of OBI-902 TROP2 ADC for the treatment of Cholangiocarcinoma has been granted. OBI-902 is the first OBI-developed ADC that incorporates our proprietary site-specific glycan-conjugated ADC enabling technology. Cholangiocarcinoma is a rare and lethal malignancy with fewer than 50,000 patients in the United States and a 5-year survival rate ranging from 2% and 23% depending on disease stage, histological subtype, and localization 1 . At present, there are no FDA approved ADC therapies for cholangiocarcinoma. To encourage the industry to develop new treatment options for rare diseases, the US FDA grants Orphan Drug Designation to exper
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom